Cartilage Degeneration Market Report 2026

Cartilage Degeneration Market Overview

• Cartilage Degeneration market size has reached to $13.4 billion in 2025 • Expected to grow to $17.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Obesity-Related Factors Fueling Growth In The Cartilage Degeneration Market • Market Trend: Innovation In Implant Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cartilage Degeneration Market?

Cartilage degeneration refers to the gradual deterioration or breakdown of cartilage tissue, a smooth, flexible connective tissue covering the ends of bones in joints. Cartilage is a cushion that allows for smooth joint movement by reducing bone friction. Cartilage degeneration leads to pain, stiffness, and decreased joint function. The main procedures of cartilage degeneration are joint replacements, chondroplasty, osteochondral transplants, microfracture, meniscus transplants, cell-based cartilage resurfacing, autologous chondrocyte implantation, and others. Joint replacements are a surgical procedure in which a damaged or diseased joint is replaced with an artificial joint, known as a prosthesis. These are used for various applications such as knee, hip, and others by different end users including hospitals and specialty clinics, ambulatory surgical centers, and academic and research institutes.

What Is The Cartilage Degeneration Market Growth Forecast?

The cartilage degeneration market size is expected to see strong growth in the next few years. It will grow to $17.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing investments in regenerative medicine research, rising demand for biologic cartilage repair solutions, expansion of stem cell-based therapies, growing focus on personalized orthopedic care, increasing adoption of advanced cartilage restoration procedures. Major trends in the forecast period include increasing adoption of cell-based cartilage repair techniques, growing use of minimally invasive surgical procedures, rising demand for regenerative medicine solutions, expansion of advanced imaging and diagnostic tools, enhanced focus on long-term joint preservation.

Global Cartilage Degeneration Market Segmentation

1) By Procedure: Joint Replacements, Chondroplasty, Osteochondral Transplants, Microfracture, Meniscus Transplants, Cell-Based Cartilage Resurfacing, Autologous Chondrocyte Implantation, Other Procedures 2) By Application: Knee, Hip, Other Applications 3) By End User: Hospitals And Specialty Clinics, Ambulatory Surgical Centers, Academic And Research Institutes Subsegments: 1) By Joint Replacements: Knee Replacement (Partial, Total), Hip Replacement (Partial, Total), Shoulder Replacement (Total, Reverse), Other Joints (Ankle, Elbow, Wrist) 2) By Chondroplasty: Radiofrequency Ablation Chondroplasty, Mechanical Chondroplasty, Thermal Chondroplasty, Arthroscopic Chondroplasty 3) By Osteochondral Transplants: Autografts (OATS), Allografts (Fresh Osteochondral Allografts), Synthetic Implants 4) By Microfracture: Traditional Microfracture, Augmented Microfracture (with scaffolds or matrix implants) 5) By Meniscus Transplants: Allograft Meniscus Transplantation (Cryopreserved, Fresh Frozen), Synthetic Meniscus Implants 6) By Cell-Based Cartilage Resurfacing: Autologous Cell-Based Therapy, Allogeneic Cell-Based Therapy, Stem Cell-Based Cartilage Repair 7) By Autologous Chondrocyte Implantation (ACI): First-Generation ACI, Second-Generation ACI, Third-Generation ACI (MACI) 8) By Other Procedures: Arthroscopic Debridement, Osteotomy, Cartilage Repair Using Synthetic Scaffolds, Injection-Based Therapies (Hyaluronic Acid, PRP, Stem Cell Injections)

What Is The Driver Of The Cartilage Degeneration Market?

The increasing prevalence of obesity is expected to propel the growth of the cartilage degeneration market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat to the extent that it may harm a person's health. Obesity can initiate and accelerate cartilage degeneration by increasing cartilage compressive forces and inflammatory cytokines. Obesity induces several pathological changes to the whole knee joint structure, including abnormal loading on the joint, joint malalignment, and muscle weakness. For instance, in November 2024, according to the National Health Service (NHS) Digital, a UK government health data agency, the prevalence of obesity among children aged 4 to 5 years increased from 9.2% in 2022/23 to 9.6% in 2023/24. Therefore, the increasing prevalence of obesity is driving the growth of the cartilage degeneration industry.

Key Players In The Global Cartilage Degeneration Market

Major companies operating in the cartilage degeneration market are Johnson & Johnson Services Inc., MEDIPOST Co. Ltd., Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings Inc., Smith and Nephew plc, Osiris Therapeutics Inc., Arthrex Inc., Conmed Corporation, Orthocell Ltd., Bioventus LLC, Aesculap Inc., Vericel Corporation, Anika Therapeutics Inc., Geistlich Pharma AG, MatTek Corporation, Breg Inc., Isto Biologics Inc., OrthoTrophix LLC, CellGenix GmbH, CartiHeal Inc., Cayenne Medical Inc., Collagen Solutions plc, Regentis Biomaterials Ltd., Histogen Inc., BioTime Inc., CollPlant Holdings Ltd.

Global Cartilage Degeneration Market Trends and Insights

Major companies operating in the cartilage degeneration market are focusing on regenerative therapies to gain a competitive advantage. Regenerative therapies involve using advanced biological techniques to restore or replace damaged cartilage, promoting natural healing processes. For instance, in 2023, Zimmer Biomet, a US-based medical device company, launched its Tissue Regeneration System, which utilizes a proprietary scaffold technology designed to enhance cartilage repair. This system features biocompatible materials that support cell growth and integration into surrounding tissues, significantly improving healing outcomes. Additionally, it offers customizable options tailored to individual patient needs, thereby enhancing its effectiveness. These innovations reflect a broader shift towards personalized medicine in the treatment of cartilage degeneration, addressing the increasing prevalence of osteoarthritis and sports-related injuries while fostering faster recovery times and improved patient satisfaction.

What Are Latest Mergers And Acquisitions In The Cartilage Degeneration Market?

In January 2024, Smith & Nephew plc, a UK-based medical-device manufacturer specializing in orthopedics, sports medicine, and advanced wound management, acquired CartiHeal Ltd. for an undisclosed amount. With this acquisition, Smith & Nephew gains access to CartiHeal’s Agili-C implant technology for cartilage and osteochondral defect repair, thereby expanding its sports-medicine and joint-preservation portfolio while enhancing its ability to offer regenerative, off-the-shelf treatment options for knee-joint lesions. CartiHeal Ltd. is an Israel-based medical-technology company, develops a cell-free, aragonite-based scaffold implant designed to stimulate natural cartilage and bone regeneration, known for treating cartilage damage without requiring donor tissue, cells, or growth factors.

Regional Outlook

North America was the largest region in the cartilage degeneration market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cartilage Degeneration Market?

The cartilage degeneration market consists of revenues earned by entities by provide services such as diagnosis and evaluation, non-surgical management, patient education, physical therapy, and nutritional and lifestyle guidance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cartilage degeneration market also includes sales of over-the-counter medications, joint supplements, topical pain relievers, and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cartilage Degeneration Market Report 2026?

The cartilage degeneration market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cartilage degeneration industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.